HK1208186A1 - Drug protein conjugates - Google Patents
Drug protein conjugatesInfo
- Publication number
- HK1208186A1 HK1208186A1 HK15108931.8A HK15108931A HK1208186A1 HK 1208186 A1 HK1208186 A1 HK 1208186A1 HK 15108931 A HK15108931 A HK 15108931A HK 1208186 A1 HK1208186 A1 HK 1208186A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- protein conjugates
- drug protein
- drug
- conjugates
- protein
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261717743P | 2012-10-24 | 2012-10-24 | |
PCT/GB2013/052662 WO2014064424A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1208186A1 true HK1208186A1 (en) | 2016-02-26 |
Family
ID=49488609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108931.8A HK1208186A1 (en) | 2012-10-24 | 2015-09-11 | Drug protein conjugates |
Country Status (20)
Country | Link |
---|---|
US (1) | US20150283259A1 (de) |
EP (1) | EP2911696B1 (de) |
JP (1) | JP6328649B2 (de) |
KR (1) | KR20150085808A (de) |
CN (1) | CN104755106B (de) |
AU (1) | AU2013336410B2 (de) |
BR (1) | BR112015008311A2 (de) |
CA (1) | CA2884359A1 (de) |
DK (1) | DK2911696T3 (de) |
ES (1) | ES2652513T3 (de) |
HK (1) | HK1208186A1 (de) |
HU (1) | HUE037604T2 (de) |
IL (1) | IL237673A0 (de) |
IN (1) | IN2015DN02577A (de) |
MX (1) | MX2015005124A (de) |
NO (1) | NO2789793T3 (de) |
RU (1) | RU2015119557A (de) |
SG (1) | SG11201501955VA (de) |
WO (1) | WO2014064424A1 (de) |
ZA (1) | ZA201501996B (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA38496B2 (fr) | 2013-03-15 | 2021-01-29 | Regeneron Pharma | Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques |
WO2014194030A2 (en) * | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6608823B2 (ja) | 2013-08-26 | 2019-11-20 | レゲネロン ファーマシューティカルス,インコーポレーテッド | マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用 |
US10406198B2 (en) * | 2014-05-23 | 2019-09-10 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
US10835616B2 (en) | 2014-10-14 | 2020-11-17 | Polytherics Limited | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG |
GB2531715A (en) * | 2014-10-24 | 2016-05-04 | Polytherics Ltd | Novel drug conjugates |
ES2960741T3 (es) * | 2014-10-24 | 2024-03-06 | Abzena Uk Ltd | Conjugados y reactivos de conjugación |
EP3319936A4 (de) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | Brückenlinker zur konjugation von zellbindenden molekülen |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
EP3331569A1 (de) * | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung |
CN108779127B (zh) | 2016-01-25 | 2022-07-05 | 里珍纳龙药品有限公司 | 美登素类化合物衍生物、其偶联物和使用方法 |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
US11273224B2 (en) | 2016-04-14 | 2022-03-15 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-CH2—CH2—O-) units in a ring |
GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
US11485792B2 (en) | 2016-06-06 | 2022-11-01 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
GB201615725D0 (en) * | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
KR20220150408A (ko) | 2016-11-14 | 2022-11-10 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
AU2019452577B2 (en) | 2019-06-29 | 2023-08-24 | Hangzhou Dac Biotech Co., Ltd. | Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor |
US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
AU2021337687A1 (en) | 2020-09-04 | 2023-03-23 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
EP4308242A1 (de) | 2021-03-17 | 2024-01-24 | Molecular Templates, Inc. | Pd-l1-bindende proteine mit shigatoxin-a-untereinheitsgerüsten und cd8+-t-zellantigenen |
CN117147824A (zh) * | 2022-05-29 | 2023-12-01 | 菲鹏生物股份有限公司 | 一种抗体缀合物及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
ES2697327T3 (es) * | 2003-11-06 | 2019-01-23 | Seattle Genetics Inc | Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador |
JP5290756B2 (ja) * | 2005-09-26 | 2013-09-18 | メダレックス インコーポレイテッド | 抗体−薬剤コンジュゲート及びその使用 |
KR101658083B1 (ko) * | 2007-10-19 | 2016-09-30 | 시애틀 지네틱스, 인크. | 씨디19 결합제 및 그의 용도 |
EP2276506A4 (de) * | 2008-04-30 | 2014-05-07 | Immunogen Inc | Wirkungsstarke konjugate und hydrophile binder |
US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
TW201117814A (en) * | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
US20150125473A1 (en) * | 2012-06-19 | 2015-05-07 | Polytherics Limited | Novel process for preparation of antibody conjugates and novel antibody conjugates |
-
2012
- 2012-04-24 NO NO14172620A patent/NO2789793T3/no unknown
-
2013
- 2013-10-11 EP EP13783360.4A patent/EP2911696B1/de active Active
- 2013-10-11 US US14/437,571 patent/US20150283259A1/en not_active Abandoned
- 2013-10-11 ES ES13783360.4T patent/ES2652513T3/es active Active
- 2013-10-11 SG SG11201501955VA patent/SG11201501955VA/en unknown
- 2013-10-11 HU HUE13783360A patent/HUE037604T2/hu unknown
- 2013-10-11 KR KR1020157009803A patent/KR20150085808A/ko not_active Application Discontinuation
- 2013-10-11 CN CN201380055945.7A patent/CN104755106B/zh active Active
- 2013-10-11 AU AU2013336410A patent/AU2013336410B2/en active Active
- 2013-10-11 BR BR112015008311A patent/BR112015008311A2/pt not_active Application Discontinuation
- 2013-10-11 WO PCT/GB2013/052662 patent/WO2014064424A1/en active Application Filing
- 2013-10-11 JP JP2015538561A patent/JP6328649B2/ja active Active
- 2013-10-11 IN IN2577DEN2015 patent/IN2015DN02577A/en unknown
- 2013-10-11 DK DK13783360.4T patent/DK2911696T3/en active
- 2013-10-11 MX MX2015005124A patent/MX2015005124A/es unknown
- 2013-10-11 RU RU2015119557A patent/RU2015119557A/ru not_active Application Discontinuation
- 2013-10-11 CA CA2884359A patent/CA2884359A1/en not_active Abandoned
-
2015
- 2015-03-11 IL IL237673A patent/IL237673A0/en unknown
- 2015-03-23 ZA ZA2015/01996A patent/ZA201501996B/en unknown
- 2015-09-11 HK HK15108931.8A patent/HK1208186A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20150085808A (ko) | 2015-07-24 |
CA2884359A1 (en) | 2014-05-01 |
SG11201501955VA (en) | 2015-04-29 |
BR112015008311A2 (pt) | 2017-07-04 |
IN2015DN02577A (de) | 2015-09-11 |
WO2014064424A1 (en) | 2014-05-01 |
EP2911696B1 (de) | 2017-09-20 |
CN104755106B (zh) | 2018-03-13 |
NO2789793T3 (de) | 2018-01-27 |
JP6328649B2 (ja) | 2018-05-23 |
MX2015005124A (es) | 2015-10-29 |
ES2652513T3 (es) | 2018-02-02 |
JP2015536329A (ja) | 2015-12-21 |
HUE037604T2 (hu) | 2018-09-28 |
DK2911696T3 (en) | 2018-01-08 |
US20150283259A1 (en) | 2015-10-08 |
ZA201501996B (en) | 2016-01-27 |
CN104755106A (zh) | 2015-07-01 |
EP2911696A1 (de) | 2015-09-02 |
IL237673A0 (en) | 2015-04-30 |
AU2013336410A1 (en) | 2015-04-09 |
RU2015119557A (ru) | 2016-12-20 |
AU2013336410B2 (en) | 2017-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2300020I1 (hu) | Pirrolobenzodiazepin-antitest konjugátumok | |
HK1208186A1 (en) | Drug protein conjugates | |
HRP20181646T1 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
HK1208187A1 (en) | Drug protein conjugates | |
HK1221153A1 (zh) | 抗體-藥物綴合物 | |
HK1210477A1 (en) | Antibody drug conjugate | |
IL236323A0 (en) | Drug conjugates of anti–cd70 antibody | |
ZA201502523B (en) | Pyrrolobenzodiazepine-anitbody conjugates | |
ZA201502267B (en) | Pyrrolobenzodiazepine-anti-her2 antibody conjugates | |
RS56520B1 (sr) | Pirolobenzodiazepin-anti-cd22 konjugati antitela | |
EP2841103A4 (de) | Dr5-liganden-arzneimittelkonjugate | |
EP2917244A4 (de) | Aus aprotinin gewonnene antikörperkonjugate | |
AP2015008208A0 (en) | Pharmaceutical administration forms comprising | |
EP2883547A4 (de) | Medizin | |
HK1215789A1 (zh) | 藥物組合 | |
HK1209339A1 (en) | Pharmaceutical formulations | |
GB201213672D0 (en) | Protein | |
GB201215901D0 (en) | Protein modification | |
GB201211403D0 (en) | Pharmaceutical formulations | |
GB201211406D0 (en) | Pharmaceutical formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20211010 |